Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028
| Published: Nov 2023 | Pages: 151 | SKU: IRTNTR76783 |
Primary Biliary Cholangitis (PBC) Therapeutics Market Forecast 2024-2028
The Primary Biliary Cholangitis (PBC) Therapeutics Market size is estimated to grow by USD 346.85 million at a CAGR of 8.75% between 2023 and 2028.
The advent of telehealth and remote monitoring has significantly contributed to the market growth. In addition, the pandemic in 2020 accelerated the adoption of telehealth services, transforming healthcare delivery. Moreover, telehealth enables remote consultations, diagnosis, treatment, and monitoring for primary biliary cholangitis patients and others, improving access to care. In addition, telehealth platforms allow primary biliary cholangitis patients to consult specialists virtually. Hence, such factors are positively impacting the market.
What will be the size of the Market During the Forecast Period?
To learn more about this report, Request Free Sample
Market Segmentation By Type, Distribution Channel, and Geography Analysis
In the realm of clinical trials subgrouping methodologies such as biomarker-based classification and symptom-based segmentation allow for more targeted and personalized approaches to treatment. Furthermore, liver function stage grouping and disease severity classification aid in stratifying patient populations based on specific criteria. Through therapeutic regimen differentiation and drug mechanism categorization, researchers can tailor interventions to suit the unique needs of different patient groups.
Type Analysis
The primary drug segment is estimated to witness significant growth during the forecast period. There has been an increasing demand for the primary drug segment which is contributing to the dominant position of this segment in the market.
Get a glance at the market contribution of various segments Download PDF Sample
The primary drug segment was the largest segment and was valued at USD 271.39 million in 2018. Moreover, factors including high adoption of the primary drug for the treatment of primary biliary cholangitis and the effectiveness of the primary drug, coupled with the rise in the number of patients suffering from primary biliary cholangitis and the availability of various primary drugs in the pipeline is fuelling this segment. Hence, such factors are fuelling this segment which in turn drives the market growth during the forecast period.
Distribution Channel
The growth of the drug stores and retain pharmacies segment in the global market is fuelled by the high sales of drugs from the drug stores and retail pharmacies. In addition, the geriatric population is more vulnerable to a number of diseases and increases the dependence on drug stores. Moreover, factors including the expanding geriatric population, increasing awareness and screening efforts, and the preference for outpatient care and follow-up treatment outside of hospital settings contribute to the drug stores and retail pharmacies segment in the market. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
Regional Analysis
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 50% to the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are contributing to the market growth in North America include the increase in the number of clinical trials, the availability of advanced healthcare facilities, and increasing healthcare expenditure from government organizations. Moreover, factors including the increasing awareness and the growing need for treating it in its early stages are contributing to the regional market growth. In addition, the presence of advanced healthcare infrastructure in the region and the availability of various patient assistance programs fuels the market growth in the region. Hence, such factors are driving the market growth in North America during the forecast period.
Key Market Players
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market growth analysis report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Abbott Laboratories: The company offers primary biliary cholangitis therapeutic treatment under rapid diagnostics, which includes infectious disease, cardiometabolic and informatics, toxicology, and consumer diagnostics.
- AbbVie Inc.
- Alkem Laboratories Ltd.
- Eli Lilly and Co.
- GENFIT SA
- Glenmark Pharmaceuticals Ltd.
- ICE S.p.a.
- Intercept Pharmaceuticals Inc.
- Ipsen Pharma
- Leeford Healthcare Ltd.
- NGM Biopharmaceuticals Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Lifesciences Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Key Drivers, Trends, Challenges, and Customer Landscape
In recent years, significant clinical trial advancements have been made in methodologies, particularly in the field of immunotherapy research. Despite these strides, treatment adherence challenges persist, posing obstacles to effective healthcare delivery. Additionally, regulatory approval processes continue to evolve to accommodate emerging therapies and ensure patient safety. Efforts to identify biomarkers for targeted treatments have intensified, paving the way for more personalized medicine approaches. These developments have profound healthcare policy implications, shaping regulations and guidelines to support the integration of innovative therapies into clinical practice.
Market Trends
A key factor shaping the market growth is the increasing demand for R&D due to government healthcare expenditure. In several applications, from small laboratory studies to large-scale production of specialty pharmaceutical products, the ability to obtain an enriched sample of small molecules, cells, proteins, nucleic acids, or clean solutions is essential. In addition, complying with government regulations that deal with the purity and consistency of primary biliary cholangitis therapeutics requires a well-thought-out enrichment plan.
Moreover, several specialties pharmaceutical companies are investing heavily in R&D. For instance, on average, the pharmaceutical company spends around 15%-20% of its revenue on R&D activities. In addition, increased R&D spending by pharmaceutical manufacturers is expected to increase the number of therapeutics in the market which is positively impacting the market. Therefore, it is expected to drive the market trends during the forecast period.
Market Challenges
Stringent government regulations is one of the key challenges hindering market growth. Several market players are offering primary biliary cholangitis therapeutics that are subject to government regulations, such as the US Food and Drug Administration (US FDA), the conformite European (CE) Marking in Europe, and other regulations in different regions and countries worldwide. In addition, commercialization of these products with different technologies is a challenging process.
Moreover, they require premarket approval from notified bodies, including private organizations recognized by the European Free Trade Association. In addition, these devices cannot be marketed without successfully completing clinical trials, which is time-consuming, expensive, and uncertain. Furthermore, the laws and regulations of the approval process vary across countries, which is a major challenge faced by multinational companies. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder market growth during the forecast period.
Key Customer Landscape
The market research and growth report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
Market Analyst Overview
The Primary Biliary Cholangitis (PBC) Therapeutics Market addresses the complexities of this chronic autoimmune liver disease, targeting the small bile ducts to prevent liver damage. With genetic predispositions and environmental triggers contributing to its onset, therapeutic interventions like ursodeoxycholic acid and obeticholic acid aim to alleviate symptoms and slow disease progression. In regions like Asia-Pacific, particularly among the Japanese population, research and development efforts focus on identifying novel drug targets and exploring combination therapies. Companies like HighTide Therapeutics with HTD1801 are addressing unmet medical needs, combating the lack of awareness and limited treatment options. Advancements in PBC therapeutics, coupled with product approvals and strategic agreements, drive accessibility through e-commerce sales and logistics services, facilitating diverse payment options for patients worldwide.
Segment Overview
The market forecasting report covers market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
- Type Outlook
- Primary drug
- Secondary drug
- Distribution Channel Outlook
- Drug stores and retail pharmacies
- Hospital pharmacies
- Online pharmacies
- Geography Outlook
- North America
- The U.S.
- Canada
- Europe
- The U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- Rest of the World (ROW)
- Australia
- Argentina
- Brazil
- North America
|
Primary Biliary Cholangitis Therapeutics Market Scope |
|
|
Market Report Coverage |
Details |
|
Page number |
151 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.75% |
|
Market Growth 2024-2028 |
USD 346.85 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.0 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 50% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Eli Lilly and Co., GENFIT SA, Glenmark Pharmaceuticals Ltd., ICE S.p.a., Intercept Pharmaceuticals Inc., Ipsen Pharma, Leeford Healthcare Ltd., NGM Biopharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
What are the Key Data Covered in this Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the market between 2024 and 2028
- Precise estimation of the market size and its contribution to the market in focus on the parent market
- Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
- Companies landscape comparing criticality of inputs and factors of differentiation
- Exclusive Matrix on companies' position and classification
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of market companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2023
- 3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global primary biliary cholangitis therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global primary biliary cholangitis therapeutics market 2018 - 2022 ($ million)
- 4.2 Type Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ million)
- 4.3 Distribution Channel Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ million)
- 4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
- 4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type
- 6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
- 6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type
- 6.3 Primary drug - Market size and forecast 2023-2028
- Exhibit 34: Chart on Primary drug - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Primary drug - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Primary drug - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Primary drug - Year-over-year growth 2023-2028 (%)
- 6.4 Secondary drug - Market size and forecast 2023-2028
- Exhibit 38: Chart on Secondary drug - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Secondary drug - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Secondary drug - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Secondary drug - Year-over-year growth 2023-2028 (%)
- 6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ million)
- Exhibit 43: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
- 7.2 Comparison by Distribution Channel
- Exhibit 46: Chart on Comparison by Distribution Channel
- Exhibit 47: Data Table on Comparison by Distribution Channel
- 7.3 Drug stores and retail pharmacies - Market size and forecast 2023-2028
- Exhibit 48: Chart on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 49: Data Table on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 50: Chart on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
- 7.4 Hospital pharmacies - Market size and forecast 2023-2028
- Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
- 7.5 Online pharmacies - Market size and forecast 2023-2028
- Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
- 7.6 Market opportunity by Distribution Channel
- Exhibit 60: Market opportunity by Distribution Channel ($ million)
- Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
- 9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
- 9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
- 9.8 Canada - Market size and forecast 2023-2028
- Exhibit 87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
- 9.9 Germany - Market size and forecast 2023-2028
- Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
- 9.10 China - Market size and forecast 2023-2028
- Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
- 9.11 UK - Market size and forecast 2023-2028
- Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
- 9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 108: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 109: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification
- 12.3 Abbott Laboratories
- Exhibit 111: Abbott Laboratories - Overview
- Exhibit 112: Abbott Laboratories - Business segments
- Exhibit 113: Abbott Laboratories - Key news
- Exhibit 114: Abbott Laboratories - Key offerings
- Exhibit 115: Abbott Laboratories - Segment focus
- 12.4 AbbVie Inc.
- Exhibit 116: AbbVie Inc. - Overview
- Exhibit 117: AbbVie Inc. - Product / Service
- Exhibit 118: AbbVie Inc. - Key news
- Exhibit 119: AbbVie Inc. - Key offerings
- 12.5 Alkem Laboratories Ltd.
- Exhibit 120: Alkem Laboratories Ltd. - Overview
- Exhibit 121: Alkem Laboratories Ltd. - Business segments
- Exhibit 122: Alkem Laboratories Ltd. - Key news
- Exhibit 123: Alkem Laboratories Ltd. - Key offerings
- Exhibit 124: Alkem Laboratories Ltd. - Segment focus
- 12.6 Eli Lilly and Co.
- Exhibit 125: Eli Lilly and Co. - Overview
- Exhibit 126: Eli Lilly and Co. - Product / Service
- Exhibit 127: Eli Lilly and Co. - Key news
- Exhibit 128: Eli Lilly and Co. - Key offerings
- 12.7 GENFIT SA
- Exhibit 129: GENFIT SA - Overview
- Exhibit 130: GENFIT SA - Product / Service
- Exhibit 131: GENFIT SA - Key offerings
- 12.8 Glenmark Pharmaceuticals Ltd.
- Exhibit 132: Glenmark Pharmaceuticals Ltd. - Overview
- Exhibit 133: Glenmark Pharmaceuticals Ltd. - Product / Service
- Exhibit 134: Glenmark Pharmaceuticals Ltd. - Key offerings
- 12.9 ICE S.p.a.
- Exhibit 135: ICE S.p.a. - Overview
- Exhibit 136: ICE S.p.a. - Product / Service
- Exhibit 137: ICE S.p.a. - Key offerings
- 12.10 Intercept Pharmaceuticals Inc.
- Exhibit 138: Intercept Pharmaceuticals Inc. - Overview
- Exhibit 139: Intercept Pharmaceuticals Inc. - Product / Service
- Exhibit 140: Intercept Pharmaceuticals Inc. - Key offerings
- 12.11 Ipsen Pharma
- Exhibit 141: Ipsen Pharma - Overview
- Exhibit 142: Ipsen Pharma - Business segments
- Exhibit 143: Ipsen Pharma - Key offerings
- Exhibit 144: Ipsen Pharma - Segment focus
- 12.12 Leeford Healthcare Ltd.
- Exhibit 145: Leeford Healthcare Ltd. - Overview
- Exhibit 146: Leeford Healthcare Ltd. - Key offerings
- 12.13 NGM Biopharmaceuticals Inc.
- Exhibit 147: NGM Biopharmaceuticals Inc. - Overview
- Exhibit 148: NGM Biopharmaceuticals Inc. - Key offerings
- 12.14 Novartis AG
- Exhibit 149: Novartis AG - Overview
- Exhibit 150: Novartis AG - Business segments
- Exhibit 151: Novartis AG - Key offerings
- Exhibit 152: Novartis AG - Segment focus
- 12.15 Teva Pharmaceutical Industries Ltd.
- Exhibit 153: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 154: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 155: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 156: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 157: Teva Pharmaceutical Industries Ltd. - Segment focus
- 12.16 Viatris Inc.
- Exhibit 158: Viatris Inc. - Overview
- Exhibit 159: Viatris Inc. - Business segments
- Exhibit 160: Viatris Inc. - Key news
- Exhibit 161: Viatris Inc. - Key offerings
- Exhibit 162: Viatris Inc. - Segment focus
- 12.17 Zydus Lifesciences Ltd.
- Exhibit 163: Zydus Lifesciences Ltd. - Overview
- Exhibit 164: Zydus Lifesciences Ltd. - Business segments
- Exhibit 165: Zydus Lifesciences Ltd. - Key offerings
- Exhibit 166: Zydus Lifesciences Ltd. - Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 167: Inclusions checklist
- Exhibit 168: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 169: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 170: Research methodology
- Exhibit 171: Validation techniques employed for market sizing
- Exhibit 172: Information sources
- 13.5 List of abbreviations
- Exhibit 173: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
primary biliary cholangitis therapeutics market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis